Clinical significance of serum hyaluronan in chronic fibrotic interstitial pneumonia

Respirology

Volumn 18, Issue 8, 2013, Pages 1236-1243

  Inokoshi, Yayoi ^a   Tanino, Yoshinori ^a   Wang, Xintao ^a   Sato, Suguru ^a   Fukuhara, Naoko ^a   Nikaido, Takefumi ^a   Fukuhara, Atsuro ^a   Saito, Junpei ^a   Frevert, Charles W ^b   Munakata, Mitsuru ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

acute exacerbation; CXCL8; hyaluronan; idiopathic pulmonary fibrosis; interstitial pneumonia

Indexed keywords

C REACTIVE PROTEIN; HYALURONIC ACID; INTERLEUKIN 8; SURFACTANT PROTEIN D;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG LAVAGE; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; SEROLOGY;

ACUTE EXACERBATION; CXCL8; HYALURONAN; IDIOPATHIC PULMONARY FIBROSIS; INTERSTITIAL PNEUMONIA;

AGED; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HUMANS; HYALURONIC ACID; INTERLEUKIN-8; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY FIBROSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D;

EID: 84886831317     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12144     Document Type: Article

References (37)

1. Kuwano K, Miyazaki H, Hagimoto N, et al. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am. J. Respir. Cell Mol. Biol. 1999; 20: 53-60.
2. Hagimoto N, Kuwano K, Inoshima I, et al. TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J. Immunol. 2002; 168: 6470-6478.
3. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 2005; 11: 1173-1179.
4. Milman N, Kristensen MS, Bentsen K, et al. Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. Sarcoidosis 1995; 12: 38-41.
5. Bjermer L, Lundgren R, Hallgren R,. Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax 1989; 44: 126-131.
6. Demedts M, Costabel U,. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur. Respir. J. 2002; 19: 794-796.
7. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007; 176: 636-643.
8. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000; 161: 646-664.
9. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007; 132: 214-220.
10. Tanino Y, Coombe DR, Gill SE, et al. Kinetics of chemokine -glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs. J. Immunol. 2010; 184: 2677-2685.
11. Garantziotis S, Zudaire E, Trempus CS, et al. Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury. Am. J. Respir. Crit. Care Med. 2008; 178: 939-947.
12. Tanino Y, Chang MY, Wang W, et al. Syndecan-4 regulates early neutrophil migration and pulmonary inflammation in response to lipopolysaccharide. Am. J. Respir. Cell Mol. Biol. 2012; 47: 196-202.
13. Gill S, Wight TN, Frevert CW,. Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection. Anat. Rec. 2010; 293: 968-981.
14. Allen SJ, Gunnar Sedin E, Jonzon A, Wells AF, Laurent TC,. Lung hyaluronan during development: a quantitative and morphological study. Am. J. Physiol. 1991; 260: 1449-1454.
15. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296: 155-158.
16. Bensadoun ES, Burke AK, Hogg JC, et al. Proteoglycan deposition in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1996; 154: 1819-1828.
17. Zhao HW, Lü CJ, Yu RJ, et al. An increase in hyaluronan by lung fibroblasts: a biomarker for intensity and activity of interstitial pulmonary fibrosis? Respirology 1999; 4: 131-138.
18. Li Y, Jiang D, Liang J, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J. Exp. Med. 2011; 208: 1459-1471.
19. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135: 1557-1563.
20. Greene KE, King TE Jr, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 439-446.
21. Kohno N,. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J. Med. Invest. 1999; 46: 151-158.
22. Rice AJ, Wells AU, Bouros D, et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study. Am. J. Clin. Pathol. 2003; 119: 709-714.
23. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur. Respir. J. 2003; 22: 821-826.
24. Heldin P, Laurent TC, Heldin CH,. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. Biochem. J. 1989; 258: 919-922.
25. Itano N, Sawai T, Yoshida M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 1999; 274: 25085-25092.
26. Laurent TC, Fraser JR,. Hyaluronan. FASEB J. 1992; 6: 2397-2404.
27. Eberlein M, Scheibner KA, Black KE, et al. Anti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression. J. Inflamm. (Lond.) 2008; 5: 20.
28. Demedts M, Behr J, Buhl R, et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-2242.
29. El-Chemaly S, Malide D, Zudaire E, et al. Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proc. Natl Acad. Sci. U.S.A. 2009; 106: 3958-3963.
30. Lepperdinger G, Mullegger J, Kreil G,. Hyal2-less active, but more versatile? Matrix Biol. 2001; 20: 509-514.
31. Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133: 226-232.
32. Behr J, Vogelmeier C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am. J. Respir. Crit. Care Med. 1996; 154: 400-406.
33. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Inter. Med 2000; 132: 947-954.
34. Churg A, Müller NL, Silva CI, et al. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am. J. Surg. Pathol. 2007; 31: 277-284.
35. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006; 27: 143-150.
36. Reilkoff RA, Peng H, Lynne A, et al. Semaphorin 7a(+) regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2013; 187: 180-188.
37. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.